Expert Interview
Discussing Biogen's Tofersen (BIIB067), an antisense drug being evaluated as a treatment for SOD1-ALS
Ticker(s): BIIB, IONSInstitution: Massachusetts General Hospital | Harvard
- Chief of the Division of Neuromuscular Medicine, Director of the Neuromuscular Diagnostic Center, Director of the EMG lab at Mass General & Associate Professor of Neurology at Harvard Medical School.
- Currently manages ~50 patients with ALS.
- Research, clinical activities and educational/administrative pursuits have centered on his subspecialty interests of neuromuscular medicine and clinical neurophysiology (EMG), with a particular focus on Amyotrophic Lateral Sclerosis (ALS).
Despite the failed phase 3 clinical trial, how promising is Tofersen based on all the presented evidence?
Added By: max_adminIs Biomarker data enough to attain approval?
Added By: max_adminAre there other treatments being developed that are showing more promise?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
